Clinical trial / 2010
Purslane supplementation improved clinical outcomes and reduced VAS scores in patients with oral lichen planus.
A randomized double-blind placebo-controlled trial evaluated purslane versus placebo over 3 months in 37 patients with symptomatic oral lichen planus ( purslane n=20, placebo n=17). Approximately 83% of purslane patients showed partial to complete clinical improvement compared to 17% in the placebo group, with 17% of purslane patients and 73% of placebo patients showing no response. Based on VAS scores, all purslane-treated patients had partial to complete response, accompanied by a significant decrease in VAS scores at the end of the study period (p < 0.001). No serious side-effects occurred in either group.
- Study type
- Randomized double-blind placebo-controlled trial
- Who was studied
- 37 biopsy-proven symptomatic oral lichen planus (OLP) patients
- What was measured
- Visual analog scale (VAS) score and clinical improvement (lesion type and size)
THE PAPER
Efficacy of purslane in the treatment of oral lichen planus.
Agha-Hosseini F, Borhan-Mojabi K, Monsef-Esfahani HR, Mirzaii-Dizgah I, Etemad-Moghadam S, Karagah A. Phytother Res, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.